Abstract
Mineralocorticoid receptor antagonists (MRAs) inhibit the overactivation of mineralocorticoid receptors (MRs), resulting in potassium retention and diuresis, and are widely used in clinical practice. They were classified into steroidal MRAs (such as spironolactone and eplerenone) and new nonsteroidal MRAs (such as finerenone) according to the molecular structure. Three most commonly used MRs are clinically available at present, spironolactone, eplerenone and finerenone. The efficacy and safety of the three drugs differ from each in the treatment of chronic kidney disease, heart failure, hypertension and other diseases. It is, thus, of great necessary to reach a multidisciplinary expert consensus on the clinical practice of MRAs to improve the understanding of medical workers in China on steroidal and nonsteroidal MRAs, and help them with rational administration of the drugs.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
